Life Technologies Corporation today announced it has acquired Laboratoire Service International (LSI), a French-based manufacturer of animal health diagnostics. 

LSI's portfolio will be added to Life Technologies' complementary diagnostic solutions and services and leverage its distribution channels to provide the global market with a wider selection of fast and accurate tools to test for common pathogens and diseases in production animals.

"Combining the breadth of complementary solutions in our respective portfolios will benefit customers in Europe," said Nir Nimrodi, Vice President and General Manager, Food Safety and Animal Health. "LSI offers first-class diagnostic products that will enhance our market presence, while our global reach will provide new channels for these products."

"This is a very exciting development: together we have a much greater research and sales resource than ever before, and that will mean that our customers can expect even better support and more innovative products in the future," said LSI CEO Eric Sellal. 

Following the acquisition, Life Technologies now provides diagnostic solutions for a wide range of pathogens including:

• For ruminants: BVDV, BTV, MAP, IBR, Q fever, bovine TB,
• For swine: PRRS, PCV2, SIV, Salmonella,
• For poultry: Avian influenza, Newcastle disease, Gumboro disease (IBD)
• For equine: EAV, West Nile virus
  

Not for use in human diagnostic procedures. 

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent^TM, Applied Biosystems®,  Invitrogen^TM, GIBCO®, Ambion, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011.

Visit us at our website: http://www.lifetechnologies.com.